Bentley, Cardinal Health to Scale-Up Clinical Supplies for Intranasal Insulin - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Bentley, Cardinal Health to Scale-Up Clinical Supplies for Intranasal Insulin


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Exeter, NH (Sept. 19)—Specialty pharmaceutical company Bentley Pharmaceuticals (www.bentleypharm.com) has entered into an agreement with Cardinal Health (Dublin, OH, www.cardinal.com) for the scale-up of clinical supplies for Bentley’s intranasal insulin product candidate. Under current good manufacturing practices, Cardinal’s North Raleigh (NC) facility will manufacture clinical supplies for Bentley’s “CPE-125” drug delivery technology. The companies previously collaborated at Cardinal’s Research Triangle Park (NC) facility, where the product was characterized.

The platform is designed to deliver insulin through a patient’s nasal mucosa via a small nasal spray. Bentley expects to continue its intranasal insulin program through global Phase II trials this year, according to a statement by company president John A. Sedor.

On Sept. 6, 2006, Cardinal announced it had won approval from the US Food and Drug Administration to begin production at its sterile facility in North Raleigh. Ovation Pharmaceutical’s (www.ovationpharmaceuticals.com) “Panhematin” (hemin for injection) was the first commercial drug to be manufactured at the new facility, which was built in 1997 and acquired when Cardinal bought Magellan Labs in 2001.

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here